Cardiovascular disease treatment by PEGylated high-density lipoprotein particles
Atherosclerosis, a cardiovascular disease characterized by plaque in the arteries, is the leading cause of mortality in industrialized nations. Lipid abnormalities are one of the key risk factors for this disease, and drugs that modify lipids are widely used to reduce the risk of cardiovascular events. While high-density lipoproteins (HDL) such as human apolipoprotein A-I (apoAI) have the potential to be a strong therapeutic agent for cardiovascular disease, they also cause adverse biological effects if administered in large quantities. This technology is a new method for obtaining a form of human apoA-I that exhibits increased half-life in plasma and preserves its biological activity, reducing the adverse effects seen in other agents. This new form of human apoA-I may provide a new, more potent therapeutic treatment for atherosclerosis and cardiovascular disease that is safer and more effective than existing options.
Specific and efficient PEGylationHDL particles with increased half-life in blood plasmaNo decrease in biological activity of the HDL particlesPatent Information:Patent Issued (WO/2012/135046)Tech Ventures Reference: IR 2911
A therapeutic treatment of atherosclerosis and cardiovascular diseasesA method for targeted PEGylation of biological molecules
None
美國
